Humacyte
NASDAQ: HUMAMorrisville, US · Delaware corporation · 3 known investors
Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform. Its off-the-shelf vessels target vascular trauma, AV access, and peripheral artery disease (PAD), and have received FDA Regenerative Medicine Advanced Therapy designation.
BiotechHealthtechMedical Devices
Founders & leadership
LE
Laura E. NiklasonFounder
TL
Ted LithgowExecutive
PB
Paul BoyerExecutive
CS
Carrie S. CoxExecutive
Board
RA
Robert AndersonBoard director
RL
Robert LangerBoard director
BW
Brady W. DouganBoard director
MW
Max WallaceBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$274.8M disclosed across 3 rounds · 2007–2018
▶$150MraisedJun 2018 · 1 investors · BiotechnologyRule 506(b)
▶$150MraisedJun 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey H. LawsonExecutive Officer
- Paul A. BoyerExecutive Officer
- Theodore D. LithgowExecutive Officer
- Robert S. LangerDirector
- Dale A. SanderDirector
- Robert AndersonDirector
- Carrie S. CoxExecutive Officer, Director
- William TenteExecutive Officer
- Brady W. DouganDirector
- Kathleen SebeliusDirector
- Laura E. NiklasonDirector
- Max N. WallaceDirector
- Offering amount
- $150M
- Amount sold
- $150M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$75MraisedMar 2018 · 29 investors · BiotechnologyRule 506(b)
▶$75MraisedMar 2018 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- Carrie S. CoxExecutive Officer, Director
- Max WallaceDirector
- Paul BoyerExecutive Officer
- Laura NiklasonDirector
- Brady W. DouganDirector
- Robert AndersonDirector
- Theodore LithgowExecutive Officer
- Kathleen SebeliusDirector
- Dale A. SanderDirector
- Offering amount
- $75M
- Amount sold
- $75M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$49.8MraisedJan 2015 · 6 investors · BiotechnologyRule 506(b)
▶$49.8MraisedJan 2015 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert AndersonDirector
- Robert LangerDirector
- Ted LithgowExecutive Officer
- Laura E. NiklasonDirector
- Brady W. DouganDirector
- Max WallaceDirector
- Paul A. BoyerExecutive Officer
- Carrie S. CoxExecutive Officer, Director
- Offering amount
- $73.8M
- Amount sold
- $49.8M
- First sale
- Oct 2007
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapSeeking Alpha24 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Stocktwits19 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
Simply Wall St18 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
Robinhood17 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView16 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanks16 shared keywordsFinancial analysis and stock research platform.
Companies competing with Humacyte for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Humacyte do?
- Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform. Its off-the-shelf vessels target vascular trauma, AV access, and peripheral artery disease (PAD), and have received FDA Regenerative Medicine Advanced Therapy designation.
- Who founded Humacyte?
- Humacyte was founded by Laura E. Niklason.
- Who are Humacyte's investors?
- Humacyte's investors include First In Ventures, Fresenius Medical Care Ventures, Oberland Capital.
- How much funding has Humacyte raised?
- Humacyte has disclosed $274.8M raised across 3 rounds.
- Where is Humacyte headquartered?
- Humacyte is headquartered in Morrisville, US.